300267.SZ
尔康制药
SZSE · Healthcare · C 制造业 · CN
CNY 3.17
−1.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.2B | 1.1B | 1.8B | 1.9B |
| Cost of Revenue | 773.4M | 857.5M | 826.0M | 1.4B | 1.5B |
| Gross Profit | 286.2M | 308.3M | 313.7M | 364.2M | 415.6M |
| Operating Expenses | |||||
| R&D Expense | 44.2M | 45.1M | 45.2M | 57.4M | 48.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 169.7M | 185.2M | 226.0M | 267.4M | 241.5M |
| Selling & Marketing Expense | 64.6M | 59.8M | 99.6M | 138.5M | 112.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 294.2M | 306.9M | 387.8M | 477.3M | 427.1M |
| Cost and Expenses | 1.1B | 1.2B | 1.2B | 1.9B | 1.9B |
| Operating Income (EBIT) | (381.0M) | (365.0M) | (370.6M) | (206.7M) | 13.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (384.2M) | (367.8M) | (388.1M) | (198.9M) | 17.4M |
| Income Tax Expense | 29.7M | 31.5M | 4.5M | 22.9M | (19.7M) |
| Bottom Line | |||||
| Net Income | (394.8M) | (379.8M) | (373.4M) | (195.3M) | 45.9M |
| Earnings from Cont. Ops | (413.8M) | (399.3M) | (392.6M) | (221.9M) | 37.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (394.8M) | (379.8M) | (373.4M) | (195.3M) | 45.9M |
| Per Share | |||||
| Basic EPS | (CN¥0.19) | (CN¥0.18) | (CN¥0.18) | (CN¥0.09) | CN¥0.02 |
| Diluted EPS | (CN¥0.19) | (CN¥0.18) | (CN¥0.18) | (CN¥0.09) | CN¥0.02 |
| Revenue Per Share | CN¥0.52 | CN¥0.57 | CN¥0.55 | CN¥0.86 | CN¥0.91 |
| Shares | |||||
| Basic Shares Outstanding | 2.0B | 2.1B | 2.1B | 2.1B | 2.1B |
| Diluted Shares Outstanding | 2.0B | 2.1B | 2.1B | 2.1B | 2.1B |
| Profitability Metrics | |||||
| EBITDA | — | (187.1M) | (175.7M) | 359.3K | 187.7M |
| D&A | — | 177.9M | 195.0M | 207.1M | 173.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026